Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 6Not yet recruiting 2Completed 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Osteosarcoma 1Neoplasms 1Melanoma 1Lymphoma 1Endocrine Gland Neoplasms 1Depressive Disorder, Major 1Depression 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Psilocybin × Clear all
NCT05947383 2026-05-06

2Dose

Sunstone Medical

Phase 2 Active not recruiting
56 enrolled

Depression, Depressive Disorder, Major, Neoplasms

NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡